Cholangiocarcinoma Market Summary
The Cholangiocarcinoma market remains dominated by chemotherapy, though targeted and immunotherapies are emerging. In 2023, the U.S. accounted for the largest market share among the 7MM (~45,000 cases, with ~45% intrahepatic). The disease is more common in older populations, with TP53 and KRAS as the most frequent mutations. Around 80% of patients receive adjuvant treatment. Recently, therapies like PEMAZYRE, TIBSOVO, and LYTGOBI have been approved, with PEMAZYRE leading FGFR-targeted drugs. The pipeline includes key players such as TransThera, Senhwa, and Relay, with Senhwa’s CX-4945 expected to gain traction. Market outlook (2020–2034) remains highly promising.
DelveInsight’s “Cholangiocarcinoma Market Insights, Epidemiology, and Market Forecast–2034” report provides a comprehensive analysis of Cholangiocarcinoma, including historical and projected epidemiology, as well as market trends across the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. The report examines current treatment practices, emerging therapies, and the market share of individual drugs, alongside the Cholangiocarcinoma market size (2020–2034) across seven major markets. It further explores treatment algorithms, key market drivers and barriers, unmet needs, and growth opportunities to assess the true potential of the Cholangiocarcinoma market.
Unlock the full potential of the Cholangiocarcinoma Market Report to gain actionable insights into market size, growth forecasts, emerging therapies, and the strategic moves of leading pharma players @ Cholangiocarcinoma Market Forecast
Some facts of the Cholangiocarcinoma Market Report are:
- According to DelveInsight, Cholangiocarcinoma market size is expected to grow at a decent CAGR by 2034.
- In 2021, the total Cholangiocarcinoma market size was USD 786.1 million which is expected to rise during the study period (2020-2034).
- Leading Cholangiocarcinoma companies working in the market are AstraZeneca, Decalth Systems, Power Life Sciences, Genfit, Servier Affaires Médicales, Basilea Pharmaceutica, Taiho Oncology, Eisai Pharmaceuticals, TransThera Sciences, Incyte Corporation, Roche, Agios Pharmaceuticals, Servier Pharmaceuticals, and Others.
- Key Cholangiocarcinoma Therapies expected to launch in the market are PEMAZYRE (pemigatinib), TIBSOVO (ivosidenib), LYTGOBI (futibatinib), and others.
- In April 2025, Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the conditional marketing authorization of zanidatamab, an investigational dual human epidermal growth factor receptor 2 (HER2)-targeted bispecific antibody, as monotherapy for the treatment of adults with unresectable locally advanced or metastatic HER2-positive (IHC 3+)† biliary tract cancer (BTC) previously treated with at least one prior line of systemic therapy.
- In April 2025, Servier (Servier Affaires Médicales) announced an Open-Label Early Access Phase 3b Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma
- In February 2025, Eisai Inc. announced results of a Multicenter, Open-Label, Phase 2 Trial of E7090 in Subjects With Unresectable Advanced or Metastatic Cholangiocarcinoma With FGFR 2 Gene Fusion
- In January 2025, Servier announced results of a Phase 2, Open-label, Multicenter Study of Orally Administered Ivosidenib in Previously Treated Japanese Subjects With Nonresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation
- In December 2024, Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company revolutionizing drug discovery through advanced computational and experimental technologies, and Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. focused on improving treatment outcomes for patients with limited therapeutic options, announced today an exclusive global licensing agreement for lirafugratinib (RLY-4008). Lirafugratinib is a selective oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), being developed for patients with FGFR2-driven cholangiocarcinoma (CCA) and other FGFR2-altered solid tumors. The partnership follows Relay’s recent positive FDA interaction and previously reported promising data in cholangiocarcinoma and other solid tumors.
- In September 2024, Lisata Therapeutics, Inc. (Nasdaq: LSTA), a clinical-stage pharmaceutical company focused on developing innovative therapies for advanced solid tumors and other serious diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to certepetide for the treatment of cholangiocarcinoma.
- On March 2024, Genfit announced an open-label, multicenter Phase 1b/2a study to evaluate safety, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of GNS561 in combination with trametinib in Advanced KRAS Mutated Cholangiocarcinoma after failure of standard-of-care first line therapy.
- On Feb 2024, TransThera Sciences (Nanjing), Inc announced a Phase III, Randomized, Controlled, Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician’s Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR)-altered, Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma
- On March 2023, Power Life Sciences Inc announced a Clinical Study Experiences of Cholangiocarcinoma Patients to Identify Trial Attributes Affecting Completion Rates for Specific Demographic Groups.
Stay ahead with detailed updates on clinical trials, FDA/EMA approvals, and key collaborations shaping the treatment landscape. Get your copy today @ Cholangiocarcinoma Therapeutics Market
Cholangiocarcinoma Overview
Cholangiocarcinoma, also known as bile duct cancer, is a rare but aggressive form of cancer originating in the bile ducts, which transport bile from the liver to the small intestine. This cancer is classified into three types based on its location: intrahepatic (within the liver), perihilar (at the liver’s hilum), and distal (further down the bile duct). The majority of cholangiocarcinomas are adenocarcinomas, which arise from the mucus glands in the bile duct.
Risk factors for cholangiocarcinoma include primary sclerosing cholangitis, chronic liver disease, bile duct cysts, liver flukes, and certain genetic conditions. Symptoms often appear late and may include jaundice, abdominal pain, weight loss, and itching, making early detection challenging.
Diagnosis typically involves imaging studies such as MRI, CT scans, and cholangiography, along with biopsy and blood tests. Treatment options vary depending on the cancer’s stage and location but may include surgery, radiation therapy, chemotherapy, and targeted therapies. Liver transplantation is an option for some patients with early-stage disease.
Despite advances in treatment, the prognosis for cholangiocarcinoma remains poor, emphasizing the need for ongoing research and improved therapeutic strategies. Early diagnosis and multidisciplinary care are crucial for enhancing patient outcomes.
Learn more about Cholangiocarcinoma treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ Cholangiocarcinoma Treatment Market
Cholangiocarcinoma Market Outlook
The Cholangiocarcinoma market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Cholangiocarcinoma market trends by analyzing the impact of current Cholangiocarcinoma therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.
Several key companies, including TransThera Sciences, Senhwa Biosciences, Lisata Therapeutics, and Relay Therapeutics, are actively advancing their pipeline candidates for cholangiocarcinoma. In 2023, the United States represented the largest market for cholangiocarcinoma, followed by Japan, which is projected to hold the second-largest market size during 2024–2034. Within the EU4 and the UK, Italy accounted for the highest market share.
Cholangiocarcinoma Market Drivers
- Rising Incidence & Prevalence: Growing number of cholangiocarcinoma cases globally, particularly in aging populations.
- Advancements in Diagnostics: Improved imaging, biomarkers, and genetic testing enabling earlier and more accurate diagnosis.
- Emergence of Targeted Therapies & Immunotherapies: FDA approvals of PEMAZYRE (pemigatinib), TIBSOVO (ivosidenib), and LYTGOBI (futibatinib) for FGFR2 and IDH1 mutations driving growth.
- Strong R&D Pipeline: Multiple pharmaceutical and biotech companies (e.g., Senhwa, Relay, TransThera) developing innovative therapies.
- Regulatory Support: Fast Track Designations (e.g., Biosyngen’s BST02) and orphan drug incentives promoting development.
- Unmet Medical Need: Limited effective standard treatments beyond chemotherapy encourage innovation.
- Increasing Investment & Collaborations: Rising funding, partnerships, and acquisitions in oncology therapeutics.
CholangiocarcinomaMarket Barriers
- Late-Stage Diagnosis: Majority of patients are diagnosed at advanced stages, limiting treatment effectiveness.
- High Treatment Costs: Targeted therapies and immunotherapies are expensive, limiting accessibility.
- Heterogeneity of Disease: Different subtypes (intrahepatic, extrahepatic, perihilar, distal) complicate treatment development.
- Drug Resistance: Patients often develop resistance to targeted therapies, reducing long-term efficacy.
- Limited Awareness & Screening: Lack of widespread awareness and screening programs delays detection.
- Clinical Trial Challenges: Small patient population and disease complexity make recruitment and trial design difficult.
- Regulatory Hurdles: Strict approval processes and safety concerns may delay market entry.
Cholangiocarcinoma Epidemiology
Cholangiocarcinoma accounts for nearly 3% of gastrointestinal cancers worldwide and represents about 10–15% of all primary liver cancers, ranking second only to hepatocellular carcinoma. As per DelveInsight’s estimates, the United States reported approximately 14,000 incident cases of cholangiocarcinoma in 2023, with around 6,000 of these being intrahepatic cases. The disease is observed to occur predominantly in the elderly population, with the highest prevalence among individuals aged 70–79 years.
Cholangiocarcinoma Epidemiology Segmentation
- Incident Cases of Cholangiocarcinoma
- Incident Cases of Cholangiocarcinoma by tumor location
- Mutation-specific cases
- Age-specific cases
- Stage-specific cases
- Total treated cases
Explore more about Cholangiocarcinoma Epidemiology @ Cholangiocarcinoma Patient Pool Forecast
Cholangiocarcinoma Pipeline Drugs Uptake
Tinengotinib (TransThera Sciences)
Tinengotinib is a spectrum-selective kinase inhibitor in Phase III, showing antitumor activity by targeting tumor cells and modifying the tumor microenvironment. Clinical trials in the US and China suggest potential across solid tumors. The FDA granted it Fast Track Designation in 2021 and Orphan Drug Designation in 2019 for cholangiocarcinoma patients lacking standard options.
Silmitasertib (CX-4945, Senhwa Biosciences)
Silmitasertib is an oral small-molecule CK2 inhibitor that disrupts DNA repair pathways, enhancing the effects of chemotherapy. In combination with gemcitabine and cisplatin, it has shown encouraging results in advanced cholangiocarcinoma. A Phase III trial is planned following positive Phase Ib/II findings.
Cholangiocarcinoma Therapies and Key Companies
- PEMAZYRE (pemigatinib): Incyte
- TIBSOVO (ivosidenib): Agios Pharmaceuticals/Servier Pharmaceutical
- LYTGOBI (futibatinib): Taiho Pharma
- Imfinzi (durvalumab): Astrazeneca
- Melphalan: Decalth Systems
- Derazantinib: Basilea Pharmaceuticals
- Futibatinib (TAS-120): Taiho Oncology
- E7090: Eisai Pharmaceuticals
- TT-0040: TransThera Sciences (Nanjing), Inc.
Request for a sample report to understand more about the Cholangiocarcinoma pipeline development activities @ Cholangiocarcinoma Clinical Trials and FDA Approvals
Cholangiocarcinoma Therapeutics Assessment
Major key companies are working proactively in the Cholangiocarcinoma Therapeutics market to develop novel therapies which will drive the Cholangiocarcinoma treatment markets in the upcoming years are AstraZeneca (LSE: AZN), Decalth Systems (Private), Power Life Sciences (Private), Genfit (EPA: GNFT), Servier Affaires Médicales (Private), Basilea Pharmaceutica (SWX: BSLN), Taiho Oncology (Private), Eisai Pharmaceuticals (TYO: 4523), TransThera Sciences (Private), Incyte Corporation (NASDAQ: INCY), Roche (SWX: ROG), Agios Pharmaceuticals (NASDAQ: AGIO), Servier Pharmaceuticals (Private), and others.
Cholangiocarcinoma Report Key Insights
1. Cholangiocarcinoma Patient Population
2. Cholangiocarcinoma Market Size and Trends
3. Key Cross Competition in the Cholangiocarcinoma Market
4. Cholangiocarcinoma Market Dynamics (Key Drivers and Barriers)
5. Cholangiocarcinoma Market Opportunities
6. Cholangiocarcinoma Therapeutic Approaches
7. Cholangiocarcinoma Pipeline Analysis
8. Cholangiocarcinoma Current Treatment Practices/Algorithm
9. Impact of Emerging Therapies on the Cholangiocarcinoma Market
Table of Contents
1. Key Insights
2. Executive Summary
3. Cholangiocarcinoma Competitive Intelligence Analysis
4. Cholangiocarcinoma Market Overview at a Glance
5. Cholangiocarcinoma Disease Background and Overview
6. Cholangiocarcinoma Patient Journey
7. Cholangiocarcinoma Epidemiology and Patient Population
8. Cholangiocarcinoma Treatment Algorithm, Current Treatment, and Medical Practices
9. Cholangiocarcinoma Unmet Needs
10. Key Endpoints of Cholangiocarcinoma Treatment
11. Cholangiocarcinoma Marketed Products
12. Cholangiocarcinoma Emerging Therapies
13. Cholangiocarcinoma Seven Major Market Analysis
14. Attribute Analysis
15. Cholangiocarcinoma Market Outlook (7 major markets)
16. Cholangiocarcinoma Access and Reimbursement Overview
17. KOL Views on the Cholangiocarcinoma Market
18. Cholangiocarcinoma Market Drivers
19. Cholangiocarcinoma Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/competitive-intelligence-services